drugset
Drugs / Zilovertamab vedotin
last change Apr 2026 re-read 9 days ago

Zilovertamab vedotin

also known as MK-2140 · VLS-101

targets ROR1

Developed for
diffuse large B-cell lymphoma · B-cell chronic lymphocytic leukemia · Burkitt lymphoma · follicular lymphoma · mantle cell lymphoma · Richter transformation · acute myeloid leukemia · B-cell acute lymphoblastic leukemia
+13 more · estrogen-receptor positive breast cancer · Ewing sarcoma · gastric cancer · malignant pancreatic neoplasm · marginal zone lymphoma · neuroblastoma · non-small cell lung carcinoma · progesterone-receptor positive breast cancer · relapsed/refractory diffuse large B-cell lymphoma · T-cell non-Hodgkin lymphoma · triple-negative breast carcinoma · urothelial carcinoma · Waldenstrom macroglobulinemia
Investigated by
Merck Sharp & Dohme LLC · VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Trials 10

today NCT06890884 · Ph 2 NCT06717347 · Ph 3 NCT06395103 · Ph 1/2 NCT05562830 · Ph 1/2 NCT05458297 · Ph 2 NCT05406401 · Ph 2 NCT05139017 · Ph 2/3 NCT05144841 · Ph 2 NCT04504916 · Ph 2 NCT03833180 · Ph 1
20192020202120222023202420252026202720282029
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT03833180 Mar 2019 → Dec 2023 B-cell chronic lymphocytic leukemia, Burkitt lymphoma, Richter transformation, T-cell non-Hodgkin lymphoma +6 VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Completed No outcome recorded
Phase 1/22 trials
Phase 1/2 NCT06395103 Aug 2024 → Mar 2029 expected B-cell acute lymphoblastic leukemia, Burkitt lymphoma, Ewing sarcoma, diffuse large B-cell lymphoma +1 Merck Sharp & Dohme LLC Recruiting No outcome recorded
Phase 1/2 NCT05562830 Nov 2022 → Feb 2029 expected urothelial carcinoma Merck Sharp & Dohme LLC Recruiting No outcome recorded
Phase 25 trials
Phase 2 NCT06890884 Apr 2025 → Dec 2027 expected diffuse large B-cell lymphoma Merck Sharp & Dohme LLC Recruiting No outcome recorded
Phase 2 NCT05458297 Jul 2022 → May 2029 expected B-cell chronic lymphocytic leukemia, Richter transformation, follicular lymphoma, mantle cell lymphoma Merck Sharp & Dohme LLC Active not recruiting No outcome recorded
Phase 2 NCT05406401 Jul 2022 → Apr 2029 expected diffuse large B-cell lymphoma Merck Sharp & Dohme LLC Active not recruiting No outcome recorded
Phase 2 NCT05144841 Jan 2022 → Apr 2026 relapsed/refractory diffuse large B-cell lymphoma Merck Sharp & Dohme LLC Completed No outcome recorded
Phase 2 NCT04504916 Oct 2020 → Jun 2023 estrogen-receptor positive breast cancer, gastric cancer, malignant pancreatic neoplasm, non-small cell lung carcinoma +2 VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Terminated No outcome recorded Stop: Business
Phase 2/31 trial
Phase 2/3 NCT05139017 Jan 2022 → Sep 2027 expected diffuse large B-cell lymphoma Merck Sharp & Dohme LLC Recruiting No outcome recorded
Phase 31 trial
Phase 3 NCT06717347 Jan 2025 → Jul 2029 expected diffuse large B-cell lymphoma Merck Sharp & Dohme LLC Recruiting No outcome recorded

News releases announcing trial results or a regulatory action · 2

DateIssuerRelease
2025-05-30 Merck Sharp & Dohme LLC Results Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial merck.com ↗
At a pre-planned analysis, zilovertamab vedotin 1.75 mg/kg in combination with R-GemOx achieved a 56.3% objective response rate (ORR) in patients with relapsed or refractory DLBCL (n=16), with eight complete responses (CR) and one partial response (PR).
2024-12-08 Merck Sharp & Dohme LLC Results Merck’s Investigational Zilovertamab Vedotin in Combination With R-CHP Demonstrates Complete Response Rate of 100% at 1.75 mg/kg Dose in Phase 2 Trial of Previously Untreated Patients With Diffuse Large B-Cell Lymphoma merck.com ↗
At a pre-planned analysis, zilovertamab vedotin in combination with R-CHP achieved a 100% (n=15) complete response (CR) rate in patients treated with zilovertamab vedotin at 1.75 mg/kg.

All press releases naming this drug 3 releases

DateIssuerRelease

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 11 sources stand behind the page.

FieldValueCited text
Known as Zilovertamab vedotin ClinicalTrials.gov intervention name — accepted as the source's own label NCT05458297 ↗
9

NCT05144841 ↗

NCT03833180 ↗

NCT06395103 ↗

NCT05139017 ↗

NCT04504916 ↗

NCT05562830 ↗

NCT05406401 ↗

NCT06717347 ↗

NCT06890884 ↗
Known as MK-2140 “A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)” NCT03833180 ↗
Known as VLS-101 “A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)” NCT03833180 ↗
Route Intravenous “Zilovertamab vedotin administered via IV infusion per Schedule 1, 2, or 3 according to participant allocation.” NCT03833180 ↗
Target ROR1 “Zilovertamab Vedotin Targeting of ROR1 as Therapy for Lymphoid Cancers.” PMID 38319241 ↗ Oct 2021